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Abstract
Background: The functional status of a cell is expressed in its metabolic activity. We have applied
stable isotope tracing methods to determine the differences in metabolic pathways in proliferating
Rhabdomysarcoma cells (Rh30) and human primary myocytes in culture. Uniformly 13C-labeled
glucose was used as a source molecule to follow the incorporation of 13C into more than 40
marker metabolites using NMR and GC-MS. These include metabolites that report on the activity
of glycolysis, Krebs' cycle, pentose phosphate pathway and pyrimidine biosynthesis.
Results: The Rh30 cells proliferated faster than the myocytes. Major differences in flux through
glycolysis were evident from incorporation of label into secreted lactate, which accounts for a
substantial fraction of the glucose carbon utilized by the cells. Krebs' cycle activity as determined
by  13C isotopomer distributions in glutamate, aspartate, malate and pyrimidine rings was
considerably higher in the cancer cells than in the primary myocytes. Large differences were also
evident in de novo biosynthesis of riboses in the free nucleotide pools, as well as entry of glucose
carbon into the pyrimidine rings in the free nucleotide pool. Specific labeling patterns in these
metabolites show the increased importance of anaplerotic reactions in the cancer cells to maintain
the high demand for anabolic and energy metabolism compared with the slower growing primary
myocytes. Serum-stimulated Rh30 cells showed higher degrees of labeling than serum starved cells,
but they retained their characteristic anabolic metabolism profile. The myocytes showed evidence
of de novo synthesis of glycogen, which was absent in the Rh30 cells.
Conclusion: The specific 13C isotopomer patterns showed that the major difference between the
transformed and the primary cells is the shift from energy and maintenance metabolism in the
myocytes toward increased energy and anabolic metabolism for proliferation in the Rh30 cells. The
data further show that the mitochondria remain functional in Krebs' cycle activity and respiratory
electron transfer that enables continued accelerated glycolysis. This may be a common adaptive
strategy in cancer cells.
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Background
Rhabdomyosarcomas are a serious childhood cancer that
arise from a primitive muscle cell, the "rhabdomyoblast",
and fail to differentiate into striated muscle cells. These
tumors account for about 5–8% of all childhood cancers,
with a peak incidence in the 1–5 age group. Overall, 50%
of the children diagnosed with rhabdomyosarcoma sur-
vive 5 years. There are two main forms of the sarcoma,
alveolar and the less severe embryonic form. Although
there is considerable information about the origin and
progression of these tumors [1-5], much less is known
about the biochemical phenotype of these sarcomas and
how it differs from the primary myocytes of the nearby tis-
sue. Such information would be of great value not only for
understanding the basic biochemistry of these trans-
formed cells, but also for developing new therapeutics.
Here we report a study of the biochemical phenotype of
rhabdomyosarcoma cells of the embryonic variety, Rh30,
in comparison with primary myocytes, using a 13C-iso-
topomer-based metabolomic approach.
Rapidly dividing cancer cells in culture show numerous
differences from the differentiated primary cells of a com-
parable type [6-8]. In order to divide, the cell must
traverse the cell cycle repeatedly, with a concomitant dou-
bling of macromolecular content during the S and G2
phases. This requires considerable biosynthetic resources
and an energy demand far in excess of the basal rate. Bio-
synthesis of proteins, nucleic acids, lipids and complex
carbohydrates involves coupling to the hydrolysis of nucl-
eoside triphosphates (e.g. ATP and GTP in protein biosyn-
thesis, CTP and UTP in lipid and carbohydrate
biosynthesis), as well as the incorporation of carbon and
nitrogen from metabolic precursors. For cells in culture,
many of these precursors are readily available in the
medium, including essential amino acids, fatty acids and
glucose. In contrast, the precursors of nucleotides, com-
plex carbohydrates and phospholipids are absent from
the medium, and so must be synthesized de novo.
There is a hierarchy of ATP-consuming reactions in cellu-
lar function [9]. As might be expected, maintenance of ion
gradients across membranes for transport and various
macromolecular repair processes involved in cell survival
are the highest priority reactions and account for a large
fraction of the ATP consumed in quiescent (G0/G1) cells
[9-11]. Upregulating macromolecule biosynthesis in
preparation for cell division requires additional ATP
equivalents to be made. Many cancer cells have a tendency
to increase glucose uptake [12] and glycolytic flux even
under aerobic conditions, while secreting a large fraction
of the glucose carbon as lactate [13,14]. This implies a
bypass to oxidative phosphorylation, such that glycolysis
alone may account for a substantial fraction of the ATP
production. This enhanced aerobic glycolysis is known as
the Warburg effect [15-17]. A more efficient means for
energy production under aerobic conditions is to increase
the flux of acetylCoA derived from the oxidation of glu-
cose, amino acids and fatty acids into the Krebs' cycle.
Moreover, to sustain the Krebs cycle activity, it is necessary
to upregulate anaplerotic reactions that replenish carbon
diverted for biosynthesis.
Skeletal muscle uses both glycolysis and oxidative phos-
phorylation for providing energy for contraction. Under
conditions of hard exercise, glycogen stores are rapidly
depleted, and oxidative phosphorylation of fuels such as
fatty acids cannot keep up with demand. The muscle
resorts to a greatly increased rate of glycolysis (> 100 fold
[18]) and the production of lactate. Lactate, and to some
extent Ala, is exported from the myocytes into the blood,
when they are transported the liver for resynthesis into
glucose via gluconeogenesis (cf. Figure 1). These comprise
the Cori and alanine cycles [19,20]. Thus, myocytes have
the capacity to make and secrete large amounts of lactate.
The secretion of lactate via the monocarboxylate trans-
porter is often accompanied by a proton symport [21,22].
Moreover, most cells can actively export protons via vari-
ous exchangers, such as the H+/Na+ antiporter [23], Many
cancer cells pump prodigious quantities of H+ into the
extracellular environment, which may offer survival
advantages, particularly in the light of their accelerated
glycolysis [24,25].
However, it has been reported that many cancer cells
upregulate the embryonic M2 form of pyruvate kinase
(PK) which is defective in catalyzing pyruvate production
[26], so alternative substrates must be oxidized to gener-
ate ATP [27-29]. One possibility is to oxidize glutamine/
glutamate or serine ultimately to produce pyruvate,
bypassing the defective PK step, and allowing lactate pro-
duction to regenerate NAD+[26,29,30]. The relative
importance of such reactions is likely to be cell dependent
[31,32]. Fortunately, such alternative pathways are readily
distinguishable using stable isotope tracer approaches in
conjunction with NMR and mass spectrometric analysis,
which we have been developing [33-37].
Thus questions arise as to the metabolic differences
between a transformed cell and a primary (untrans-
formed) cell. Here we have used 13C quantitative iso-
topomer analysis to follow the fate of individual carbon
atoms derived from glucose, as outlined in Figure 1, in
both rhabdomyosarcoma cells (Rh30) and primary myo-
cytes, grown under the same conditions to probe their
biochemical phenotypes. This approach enabled changes
in turnover through individual pathways to be followed,
which is not generally possible by concentration-based
metabolite profiling alone. Furthermore, the use of 13C-
edited  1H NMR techniques allowed identification ofMolecular Cancer 2008, 7:79 http://www.molecular-cancer.com/content/7/1/79
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Metabolic scheme Figure 1
Metabolic scheme. Carbon flow from [U-13C]-glucose through glycolysis, Krebs cycle, PPP, pyruvate carboxylation, malate/
Asp shuttle, and synthesis of GSH and pyrimidine nucleotides as discussed in the text. Also shown are the expected 13C iso-
topomers of key metabolites in this network. Excretion of lactate and Ala into serum is part of the alanine and Cori cycles. 
Solid oval represents the plasma membrane and the dashed oval represents the mitochondrial space. Double-headed arrows: 
exchange or reversible processes. The label patterns arise from [U-13C]-glucose. Open circles: 12C; filled circles: 13C. Glc = glu-
cose, G6P = glucose-6-phosphate, Rib = nucleotide ribose, DHAP, GAP = dihydroxyacetone phosphate and glyceraldehyde-3-
phosphate, PEP = phosphoenolpyruvate, Pyr = pyruvate, Lac = lactate, Cit = citrate, 2 = OG = 2-oxoglutarate, Mal = malate, 
OAA = oxalacetate, U = uracil base. Critical enzymes are shown in cyan. HK= hexokinase (entry to glycolysis), G6PDH = glu-
cose-6-phosphate dehydrogenase (entry to the oxidative branch of the pentose phosphate pathway), TK, TA transketolase and 
transaldolase (non-oxidative pentose phosphate pathway), PK = pyruvate kinase, PDH = pyruvate dehydrogenase, PC = pyru-
vate carboxylase, AAT = aspartate amino transferase, MDH = malate dehydrogenase, ME = malic enzyme. Glutaminolysis is the 
pathway from Gln to pyruvate via ME, leading to unlabeled malate, Asp, Ala and lactate. Where two patterns are shown in the 
Krebs' cycle intermediates, this is due to the scrambling at the succinate step (first turn only). For U and OAA, the labeling 
from PC activity gives rise to a third labeling pattern, shown in red. The isotopomer pattern for U shows the three ring car-
bons (4,5,6) derived from Asp. The exchange of [13C-1,2,3]-Asp via the malate/Asp shuttle into the cytosol leads to the synthe-
sis of [13C-1,2,3]-malate.Molecular Cancer 2008, 7:79 http://www.molecular-cancer.com/content/7/1/79
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major phosphorylated sugars that are otherwise difficult
to detect in crowded 1H NMR spectra. Clear differences
between the myocytes and the Rh30 cells were evident,
consistent with heightened energy and anabolic metabo-
lism in Rh30 cells.
Results and discussion
Cell growth
Under the growth conditions of these experiments, the
Rh30 cells double in about 24 h in the presence of serum.
The growth rate in the absence of serum (0.5% BSA) was
about 30% slower, indicating only a weak dependence on
growth factors. In contrast, the primary myocytes grew
much more slowly, with a doubling time of approxi-
mately 50 h in the presence of serum growth factors. This
suggests that the cancer cells have an overall net higher
demand for metabolic energy to drive macromolecular
biosynthesis as the cells proliferate. This is in addition to
the normal basal cell metabolic requirements.
Glucose uptake and lactate secretion
The amount of glucose remaining in the medium and the
amounts of lactate and Ala that were secreted by the cells
are readily measured by 1H NMR and/or GC-MS. Further-
more, as NMR can distinguish between 13C-labeled and
12C lactate and glucose (see below), it was straightforward
to determine the fraction of lactate that derived from the
supplied 13C-glucose, or from other sources, according to
Eq. (2). Table 1 shows the data for glucose consumption
and secretion of lactate and Ala into the medium from the
two cell types.
The consumption of [U-13C]-glucose by the Rh30 cells at
24 h was comparable to the consumption by the primary
myocytes in 48 h, reflecting the slower growth rate of the
latter. The amount and degree of 13C enrichment in lactate
secreted was very much higher for the Rh30 cells than the
primary myocytes (Table 1 and Figure 4). Since the dry
weight of the myocytes at 48 h was comparable to that of
the Rh30 cells at 24 h, this implies an 8-fold higher lactate
production rate in the Rh30 cells than the myocytes. The
amount and degree of 13C enrichment of Ala in the Rh30
medium was also much higher than measured in the myo-
cyte medium, although Ala secretion constituted a smaller
fraction of the labeled glucose consumption (Table 1 and
Figure 4). Thus, the Rh30 cells converted a much higher
fraction, F (cf. Eq. 2 and Table 1) of the 13C glucose con-
sumed into lactate (50%) than the myocytes (10%). We
have observed that typically 30–50% of the glucose con-
sumed was converted to lactate by various epithelial
derived cancer cell lines, (A.N. Lane, T. WM Fan, unpub-
lished data). This is in contrast to a recent report on gliob-
lastoma cells, in which more than 95% of the glucose
consumed was converted to lactate and Ala [38]. The high
rate of production of labeled lactate in Rh30 and other
cancer cells indicates that the pyruvate kinase (PK) step in
glycolysis (Fig. 1) must be active, in contrast with the
reports of defective PK in some tumor cells [28].
The high degree of lactate labeling in Rh30 cells indicates
that the major source of carbon in lactate and Ala was
indeed glucose. However, the fraction of 13C Ala labeling
in the myocyte was essentially at natural abundance,
reflecting its primary origin from the 10% FCS present in
the medium. Thus, not only did the Ala labeling pattern
in myocytes differ from that in Rh30 cells but also it was
distinct from the lactate labeling pattern in both cell lines.
As the immediate precursor to Ala and lactate is pyruvate,
these differences in labeling patterns could indicate the
presence of distinct intracellular pools of pyruvate as
observed in other cells [39,40] and see below. Moreover,
a significant fraction of glucose taken up by Rh30 (48%)
and myocytes (90%) was converted to metabolites other
than lactate (cf. Table 1). The fate of some of the remain-
ing glucose carbon was traced in the cellular components
is described below
Glucose-dependent cell metabolism
Thirty four metabolites in the TCA extracts of the cell bio-
mass were analyzed using GC-MS (Figures 2, 3), twenty of
which were also analyzed by 1H NMR (Figure 5, 6). An
additional eight compounds were determined by 1H NMR
alone for a total of forty two identified metabolites. The
profiles of selected metabolites in Rh30 and myocytes
determined by GC-MS are compared in Figures 2 and 3.
Lactate, Gly, Thr, Glu, glutathione (GSH), Arg, and phos-
phocholine (P-choline), taurine and myo-inositol were
among the more abundant metabolites (cf. Figures 2, 3, 4,
5). There was good agreement between GC-MS and NMR
determinations, indicating high analytical reliability. Figs
2, 3, 4, 5 also illustrate that there are significant differ-
ences in levels of numerous metabolites between the
Table 1: Quantification of labeled metabolites in the media by 1H NMR analysis. 
Cell [13C Lac] mM %13CLac [13C Ala] mM %13CAla [Thr] mM [Glc] mM Δ[Glc]a mM %Glc->Lacb
Rh30 (24 h) 4.8 ± 0.6 83 ± 1 0.35 ± .03 67 ± 4 0.15 6.1 ± 0.6 4.6 ± .6 52 ± 7.5
Myocyte(48 h) 1.2 ± 0.2 64 ± 2 <0.01 <5 0.15 4.8 ± .5 5.9 ± .5 10 ± 1.4
Concentrations and 13C enrichments of selected metabolites in the medium were determined by NMR integrations as described in the Methods.
a change in medium glucose concentration (= consumption).
b percentage of glucose consumed converted to secreted lactate (cf. text).Molecular Cancer 2008, 7:79 http://www.molecular-cancer.com/content/7/1/79
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myocytes and Rh30 cells. Notably there was a much
higher content of amino acids, GSH, taurine, P-choline,
myo-inositol, adenine nucleotides (5'-AXP), and uracil
nucleotides in the Rh30 cells. The high abundance of P-
choline in Rh30 compared with the myocytes (Figure 5)
appears to be a distinct feature of proliferating cells
[35,37,41-46].
Glycolysis
Figure 6 shows an expansion of the lactate region for the
Rh30 cells shown in Fig 5. The 3-methyl resonances of
both Ala and lactate (doublets at 1.53 and 1.4 ppm,
respectively) display pairs of 13C satellite peaks displaced
126 Hz apart. These satellite peaks have a complex struc-
ture, which can be accounted for by considering addi-
tional couplings of these protons to 13C2 and 13C1 of the
compounds (i.e. uniformly labeled) [35,47]. The presence
of uniformly 13C-labeled lactate and Ala was also evident
in the high-resolution 2-D 1H-13C HSQC or the 1-D 13C
projection spectra of Rh30 and myocyte cell extracts, as
illustrated in Figure 7. The respective doublet and triplet
patterns of the β-(C3) and α-(C2) carbons of lactate and
Ala (due to 13C-13C coupling) [36] is further consistent
with the 1H TOCSY satellite patterns for these two metab-
olites (cf. Fig. 8). The NMR data were corroborated by the
GC-MS analysis, where the m+3 (lactate+3) mass iso-
topomers predominated. These data together indicate that
the three 13C in both lactate and Ala derived directly from
the [U-13C]-glucose precursor via glycolysis.
Detailed quantification of the 13C-isotopomers of intrac-
ellular lactate and Ala by NMR and GC-MS is given in
Table 2 and Fig. 3. As observed for the medium (see
above), the myocytes showed a lower degree of enrich-
ment than the Rh30 cells, especially for Ala, consistent
with a substantially lower glycolytic rate in the primary
cells. The 13C-Ala enrichment in the Rh30 cells grown in
the absence of growth factors from FCS was even lower
than that in the myocytes. There was no unlabeled Ala
present in this medium indicating that the cells under
growth factor depleted conditions were not actively
transaminating labeled pyruvate (cf. Figure 1). Thus, the
unlabeled Ala fraction may reflect contributions from
other metabolic processes such as protein turnover or
glutaminolysis [30] (cf. Figure 1) and possibly involving a
different pool of pyruvate as has been observed in other
cells [39,40]. However, the amount of protein turnover or
glutaminolysis required to account for the production of
unlabeled Ala was small owing to its low concentration
(cf. Figures 4, 5).
Krebs' cycle activity
Several other critical metabolites in the cells were also
labeled with 13C as shown by the 2-D 1H TOCSY spectrum
of an example Rh30 cell extract in Figure 8. The cross-peak
patterns are characteristic of particular metabolites, such
as the ribose moieties of nucleotides, lactate, Ala and Glu,
as annotated. Many of these cross-peaks are surrounded
by satellite peaks that denote the presence of 13C. These
are made clearer in the expansion of the spectral region of
Glu, Ala and Lac (Fig. 9). It is clear that Glu was substan-
tially labeled at the C4 (2.65 ppm) and C2 (4.08 ppm)
positions and to a lesser extent at the C3 (2.22 ppm) posi-
tion. Figure 9 also revealed the presence of four different
Glu isotopomers, i.e. 13C-2,3-Glu, 13C-2-Glu, 13C-3-Glu,
13C-2,4-Glu, 13C-4-Glu, and 13C-3,4-Glu. Additional iso-
topomer information was obtained from analysis of the
HSQC spectrum (Fig. 7). The doublet pattern of the γ- (C-
4) and α- (C-2) carbons of Glu suggests the presence of
13C-4,5-Glu and/or 13C-3,4-Glu as well as 13C-1,2-Glu
and/or  13C-2,3-Glu isotopomers, respectively. However,
the 13C satellite pattern for the TOCSY cross-peak of H3 to
H2 of Glu (2.22 to 4.08 ppm in Fig. 9) shows a significant
amount of 13C-2,3-Glu. Similarly, the dominance of 13C-
3,4-Glu is clear from the 13C satellite pattern for the cross
peak of H4 to H3 of Glu (2.65 to 4.08 ppm in Fig. 9) but
the presence of 13C-4,5-Glu or 13C-1,2-Glu could not be
ruled out with the present data.
The above results are clear evidence of de novo synthesis
of Glu from labeled glucose (10 mM), even though unla-
beled Gln (2 mM) and Glu (0.13 mM) were both present
in the medium. Further examination of the labeling pat-
tern revealed evidence for the route of synthesis for the
different Glu isotopomers. Glutamate is derives from 2-
oxoglutarate by transamination or reductive amination
(Glu dehydrogenase) in mammalian cells. There are two
routes of label incorporation from [13C-U]-glucose into 2-
oxoglutarate via pyruvate (Figures 1, 10). As shown in
detail in Figure 10, one route (Fig. 10A) involves the path-
way pyruvate → acetylCoA → citrate → 2-oxoglutarate,
which leads to the production of 13C-4,5-Glu. The other
route (Fig. 10B) utilizes the anaplerotic reaction of pyru-
vate carboxylase to produce OAA directly from pyruvate
with the subsequent reaction sequence of citrate → 2-
oxoglutarate, which generates 13C-2,3-Glu. The presence
of 13C-2,3-Glu shown in Figures 7 and 9 is consistent with
the activity of pyruvate carboxylase. The redistribution of
labels into different carbons of Glu is presumably the
result of carbon scrambling at the succinate dehydroge-
nase (SDH) step due to the symmetry of the succinate
molecule. Moreover, the presence of multiple 13C-Glu iso-
topomers described above supports multiple turns of the
cycle with 13C label input (cf. Figure 10).
It is clear from Figure 7 that the Rh30 cells had a much
higher buildup of the different 13C isotopomers of Glu
(than the myocytes. This implicates a higher turnover of
the Krebs cycle and specifically a higher capacity for ana-
plerotic pyruvate carboxylation, as evident by theMolecular Cancer 2008, 7:79 http://www.molecular-cancer.com/content/7/1/79
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enhanced buildup of 13C-4,5-Glu and 13C-2,3-Glu, respec-
tively.
Malate and aspartate also showed substantial 13C enrich-
ment (Figure 3B) in both doubly and triply labeled mass
isotopomers based on the GC-MS analysis. The positional
isotopomer of the triply labeled malate was deduced from
the 2-D HSQC analysis, as shown in Figure 7. The doublet
of C3 or β-malate and the triplet of C2 or α-malate indi-
cate the prevalence of [13C-1,2,3]-malate. The doubly
labeled malate isotopomers can be [13C-2,3]-malate, [13C-
1,2]-malate, and/or [13C-3,4]-malate, the abundance of
Concentration of metabolites in cell extracts of Rh30 cells and myocytes Figure 2
Concentration of metabolites in cell extracts of Rh30 cells and myocytes. Concentrations were determined by GC-
MS as described in the text. A, B: Total concentrations of selected metabolites normalized to cell dry weight.
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Concentration of metabolites in cell extracts of Rh30 cells and myocytes Figure 3
Concentration of metabolites in cell extracts of Rh30 cells and myocytes. Concentrations were determined by GC-
MS as described in the text. A, B: mass isotopomer concentrations of selected metabolites showing increased labeled incorpo-
ration in Rh30 cells.
A.
B.Molecular Cancer 2008, 7:79 http://www.molecular-cancer.com/content/7/1/79
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which could not be ascertained with the present data. By
comparing Rh30 cells with myocytes in terms of the 13C-
malate isotopomer patterns in Fig. 3B and 7, it is clear that
Rh30 cells synthesized a much higher amount of doubly
and triply labeled malate, the latter of which was identi-
fied as [13C-1,2,3]-malate. Similar considerations apply to
Asp i.e. the doubly and triply labeled ([13C-1,2,3]-Asp)
isotopomers were more abundant in Rh30 cells than in
myocytes (Figure 3B).
According to the schemes in Figs 1 and 10B, [13C-1,2,3]-
malate and [13C-1,2,3]-Asp can only be synthesized from
[U-13C]-pyruvate via anaplerotic pyruvate carboxylation
(PC). PC can also lead to the synthesis of the doubly
labeled [13C-2,3]-malate or Asp after one turn of the Krebs
cycle, as outlined in Fig. 10B. In contrast, the doubly
labeled malate species (as [13C-1,2]- and [13C-3,4]-
malate) or Asp should derive from the normal Krebs' cycle
sequence with input of [U-13C]-pyruvate, as illustrated in
Fig. 10A, or the doubly labeled [13C-2,3]-malate from
pyruvate carboxylation, as outlined in Fig. 10B. Thus, the
combined GC-MS and NMR determination of malate and
Asp isotopomers not only revealed an enhanced activity
of the Krebs' cycle but also activation of pyruvate carbox-
ylation in the Rh30 cells over the primary myocytes. Such
anaplerotic reactions are essential for actively dividing
cells, as the production of important metabolites such as
pyrimidine nucleobases and reduced glutathione deplete
Krebs' cycle intermediates (Fig. 1 and see below), which
must be replenished.
Krebs cycle intermediates may also be replenished via
glutaminolysis [30,38,48], which has been shown to be
activated in glioblastoma cells, based on the production
of labeled lactate derived from labeled Gln [38]. The role
of glutaminolysis in anaplerosis in Rh30 cells could not
be ascertained here for lack of carbon tracing from labeled
Gln. However, the comparable production of unlabeled
lactate by Rh30 cells and myocytes (Figures 1, 4 and see
above) suggests a minor role for glutaminolysis in activat-
ing anaplerosis in Rh30 cells.
The sustained activity of the Krebs' cycle in the Rh30 cells
requires a functional respiratory chain to regenerate NAD+
and FAD in the mitochondria. The same chain also reoxi-
dizes cytosolic NADH produced by glycolysis, and trans-
ported into the mitochondria via the malate-aspartate
shuttle (cf. Fig. 1), that is not involved in reducing pyru-
vate to lactate (and see above).
Furthermore, transformed Rh30 cells were much more
active in de novo GSH synthesis than the primary myo-
cytes. GSH was labeled in the Glu residue in Rh30 cells
and the extent of this labeling was much stronger in Rh30
cells than in the myocytes (cf. Figs. 7 and 8), just as the
case for its precursor Glu (Table 4). Although the cysteine
supply can be rate limiting in GSH synthesis, in this case
the medium contained an adequate supply of cystine (0.2
mM). The incorporation of labeled glutamate indicates a
substantial rate of de novo GSH synthesis in the Rh30
cells.
Nucleotide biosynthesis
Asp is a direct crucial precursor to pyrimidine biosynthesis
(Fig. 1). We have previously shown that the pyrimidine
rings of nucleotides become 13C labeled in the Rh30 cells
[35]. All possible isotopomers of 5'-UXP C5C6 were
observed as shown in the TOCSY spectra (Figure 9B). This
13C satellite pattern was similar to that of Asp (Figure 8),
which is consistent with Asp being a direct precursor to
the de novo synthesis of 5'UXP ring (Figures 1, and 10B).
The  13C abundance and extent of the labeling in uracil
ring of 5'-UXP (Table 3) and its precursor Asp (Figures 3B
and 7). was much higher in Rh30 cells than in myocytes.
Thus, it is clear that Rh30 cells exhibited a higher capacity
for the de novo synthesis of pyrimidine nucleotides than
myocytes.
As Asp is derived from the transamination of the Krebs'
cycle intermediate, OAA, increased diversion of Asp to
pyrimidine ring biosynthesis would ultimately deplete
OAA, which must be replenished to sustain the Krebs'
cycle activity. As described above, this can occur by
enhanced anaplerosis via pyruvate carboxylation in Rh30
cells. Furthermore, labeled Asp synthesized in the mito-
chondria is presumably transported to the cytoplasm for
pyrimidine biosynthesis via the Asp/malate shuttle (Fig.
1). The enhanced rate of pyrimidine synthesis in Rh30
cells may well reflect an increased Asp/malate shuttle
Concentration of metabolites in media from Rh30 cells and  myocytes Figure 4
Concentration of metabolites in media from Rh30 
cells and myocytes. Concentrations were determined by 
GC-MS as described in the text. Mass isotopomer concentra-
tions of lactate and Ala secreted by Rh30 cells or myocytes 
into the medium.
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activity. This shuttle also facilitates the transfer of NADH
produced in the cytoplasm to the mitochondrion for ATP
production via oxidative phosphorylation. Although pyri-
midine biosynthesis is mainly cytoplasmic, one step
occurs within the mitochondrion and involves coupling
to the electron transfer chain. Collectively these all point
to metabolically functional mitochondria in the cancer
cells.
The higher capacity for pyrimidine synthesis in Rh30 cells
is corroborated by the13C labeling data in the ribose moi-
ety of 5'-UXP, where all five carbons of the ribose residue
were uniformly labeled in 13C. This was evident from the
TOCSY  13C satellite patterns of the 5'-UXP cross-peaks
(e.g. Fig. 9B for H1' → H2' of 5'-UXP) and 13C spin cou-
pling patterns of C1' to C4' of ribose in 5'-UXP (Fig. 8).
The abundance of [U-13C-ribose]-UXP (Fig. 9B) and %
13C enrichment (Table 3) were much higher in Rh30 cells
1H NMR spectra of Rh30 and myocyte cell extracts Figure 5
1H NMR spectra of Rh30 and myocyte cell extracts. NMR spectra were recorded at 600 MHz, 20°C with a recycle time 
of 5 sec. Cells were grown in the presence 0.2% [U-13C]-glucose for 24 h (Rh30) or 48 h (myocytes). Upper myocytes, lower 
Rh30. Spectra were scaled to dry weight to show the difference in absolute concentrations of metabolitesMolecular Cancer 2008, 7:79 http://www.molecular-cancer.com/content/7/1/79
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than in myocytes, consistent with an enhanced rate of 5'-
UXP synthesis. Also evident in Fig. 8 is the higher rate of
synthesis for purine nucleotides (i.e. 5'-AXP and 5'-GXP),
as shown by the higher abundance of [U-13C-ribose]-5'-
AXP and 5'-GXP. This difference in 13C labeling of nucle-
otides is consistent with a higher metabolic demands for
macromolecular (e.g. RNA) biosynthesis for the trans-
formed cells compared with slowly dividing primary cells
(also see below).
It should also be noted that the 1H NMR resonances of 5'-
AXP and 5'-UXP in Fig. 8 were in fact mixtures of 3 reso-
nances, which correspond to the tri, di and mono phos-
phates species, with intensities in the order 5'-ATP > 5'-
ADP > 5'-AMP and similarly for 5'-UTP, 5'-UDP and 5'-
UMP (data not shown).
Intracellular glucose-6-phosphate and glycogen synthesis
Additional 2-D 1H NMR experiments helped identify 13C-
labeled glucose-6-phosphate (G6P) and/or glycogen in
the Rh30 and myocyte extracts. These included 1H HCCH-
TOCSY and 1H-13C HSQC-TOCSY. The HCCH-TOCSY
spectrum of the myocyte extract (Figure 11) displayed
covalent connectivities of protons attached to consecu-
tively 13C-labeled carbons of various metabolites such as
lactate, Ala, Glu, β-glucose-6-phosphate (βG6P), glyco-
gen, and AXP. The Rh30 spectrum (not shown) also
exhibited similar covalent networks except for the absence
of connectivities for glycogen, lower abundance connec-
tivities for βG6P, and more prominent connectivities for
5'-UXP and 5'-GXP. The connectivity patterns for these
metabolites is consistent with the presence of [13C-1-5]-
βG6P and [U-13C-glucose]-glycogen, in addition to [U-
13C]-lactate, [U-13C]-Ala, and [13C-2,3,4]-Glu.
Alanine and Lactate isotopomer patterns in Rh30 cell extract Figure 6
Alanine and Lactate isotopomer patterns in Rh30 cell extract. 1H NMR spectrum expansion of the Rh30 cell extract 
spectrum from Figure 5 showing the satellite peaks of lactate and Ala.Molecular Cancer 2008, 7:79 http://www.molecular-cancer.com/content/7/1/79
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2-D 1H-13C HSQC analysis of Rh30 cells and myocytes Figure 7
2-D 1H-13C HSQC analysis of Rh30 cells and myocytes. Both cells were cultured in [U-13C]-glucose for 24 hr before 
trichloroacetic acid extraction and HSQC measurement at 14.4 T. The spectra were recorded with 0.14 s acquisition in t2 and 
34 ms in t1. The data table in t1 was linear predicted to 1024 complex points and zero filled to 2048, so that 13C-13C couplings 
(35–45 Hz) were resolved. Panel C displays the 2-D contour map of the Rh30 cell extract while panels B and A are respectively 
the 1-D 13C projection spectra of the 2-D contour maps for Rh30 and myocytes. Both A and B were normalized to cell dry 
weight but A was plotted at 10× scale relative to B.Molecular Cancer 2008, 7:79 http://www.molecular-cancer.com/content/7/1/79
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To confirm further the assignment for G6P (as opposed to
glucose), 2-D high-resolution 1H-13C HSQC-TOCSY spec-
tra were analyzed and that for the myocytes is illustrated
in Figure 12. In this spectrum, covalent connectivities
from 13C1 to H1 then relayed to H2 and H3 as well as
13C3 to H3 then to H4 of βG6P were clearly observed. Also
evident was the set of 13C6 to H6 connectivities of βG6P,
thus providing unequivocal identification of βG6P in the
crude extract of the myocytes. Moreover, the high-resolu-
tion spectrum revealed 13C coupling patterns of βG6P car-
bons, i.e. doublet for C1, triplet for C3-5, as well as
doublet for C6, which indicate the presence of uniformly
labeled βG6P and thus its origin from [U-13C]-glucose.
Free glucose is not expected to be present in cells where
the activity of hexokinase exceeds that of glucose transport
[49]. The 1D proton spectra (Fig. 5A) show that the con-
centrations of glucose and G6P were negligible in the
TOCSY Spectra of Rh30 cell extract Figure 8
TOCSY Spectra of Rh30 cell extract. TOCSY spectrum of TCA extract of Rh30 cells grown for 24 h in the presence of 
0.2% [U-13C]-glucose and 10% FCS, using a mixing time of 50 ms and a spin lock strength of 8 kHz. Aliphatic region of the spec-
trum showing connectivities and satellite peaks for some assigned metabolites.Molecular Cancer 2008, 7:79 http://www.molecular-cancer.com/content/7/1/79
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Rh30 cells which indicates that the steps downstream of
G6P in glycolysis are not flux limiting. The low concentra-
tion of free glucose is a feature of cancer cells which
together with the low level of G6P reflects the high glyco-
lytic flux, making glucose transport rate limiting [50],
despite derepression of GLUT4 expression by mutated
p53[12]. In contrast, the concentration of G6P in the
myocytes was significant (Fig 7A), which suggests that for
these cells, the uptake of glucose or hexokinase was not
limiting glycolysis in these cells. Rather, a step down-
stream of G6P, such as PFK1, limits flux leading to an
accumulation of G6P. This is consistent with typical esti-
mates of intracellular G6P in skeletal muscle (ca. 200–400
μM)[51]. The much higher demand from glycolysis and
the PPP (see above) in Rh30 cells, compared with the
myocytes, may well be limiting glycogen synthesis, which
competes for the same glucose precursor. This may under-
lie the lack of newly synthesized glycogen in Rh30 cells
versus its significant presence in the myocytes (cf. Fig. 11).
Finally, the extent of 13C labeling in lactate, Ala, and pyri-
midine nucleotides was higher in Rh30 cells grown in
fetal calf serum (FCS) than cells grown in BSA (Table 3).
The low enrichment of the intracellular Ala may be related
to differences in pyruvate production from sources other
than glucose between the FCS-stimulated and unstimu-
lated Rh30 (BSA) cells (see above). For Glu, the two
growth conditions gave a comparable extent of 13C labe-
ling, which was significantly higher than that for the myo-
cytes. Thus, even without the influence of the growth
factor in FCS, Rh30 cells grown in BSA still exhibited a
greater turnover of [U-13C]-glucose through glycolysis,
Krebs' cycle, and pyrimidine nucleotide biosynthesis than
the primary myocytes.
Conclusion
Using [U-13C]-glucose as tracer and isotopomer-based
metabolomic analysis, we have demonstrated major dis-
tinctions in central energy and anabolic metabolism
between the primary myocyte and transformed Rh30 cell
lines. A major advantage of this approach is the ability to
follow the fate of individual atoms simultaneously into
many metabolites, and thereby to characterize the interre-
lationships among multiple biochemical pathways. Our
data show that relative to the myocytes, glycolysis, Krebs'
cycle, pentose phosphate pathway, and nucleotide bio-
synthesis (cf. Fig. 1) were coordinately enhanced in Rh30
cells, presumably to meet the demand of accelerated
growth. The coordination between energy production
(including the Warburg effect [15,17,52]) and generation
of biosynthetic precursors in Rh30 cells may well be medi-
ated via an activation of anaplerotic carboxylation and the
malate/Asp shuttle which facilitates the transfer of NADH
hydride from the cytoplasm to the mitochondrion for oxi-
dative phosphorylation [7,48], thereby sustaining acceler-
ated glycolysis. The role of glutaminolysis as another
anaplerotic input to the Krebs cycle is unclear but is likely
to be less significant in accounting for the distinction
between Rh30 cells and myocytes.
It is therefore evident that mitochondria of transformed
Rh30 cells are active, both in citric acid cycling and respi-
ratory electron transport. Since these processes are essen-
tial to cell proliferation, it is reasonable to postulate that
they may be fundamental in the transformation of pri-
mary to malignant cells.
Methods
Materials
Cells
The human RMS cell line Rh30 (established at St. Jude
Hospital), and human primary myocytes were cultured in
pyruvate and glucose-free RPMI 1640 (Invitrogen, 11879-
020), supplemented with 100 IU/ml penicillin, 10 μg/ml
streptomycin, and 50 μg/ml neomycin (Life Technologies,
Inc., Grand Island, NY) in the presence of 10% heat-inac-
tivated FCS (Life Technologies) and 0.2% glucose. The
medium thus contained 0.17 mM 12C alanine and 0.5
mM unlabeled lactate and 0.56 mM unlabeled glucose
from the FCS. The cells were cultured in a humidified
atmosphere at 5% CO2, 37°C at an initial cell density of
2.5 × 104  cells/flask (Corning) and the media were
changed every 48 h. Prior to 13C labeling the cells were
grown in 0.5% bovine serum albumin (BSA), without FCS
to partially synchronize the culture. Control experiments
were also run under otherwise identical conditions in
which 0.5% BSA was used in place of FCS during the labe-
ling phase. The dry weight of cells was measured for nor-
malizing metabolite concentrations.
Isotopes
[U-13C]-glucose (99% 13C) was purchased from Cam-
bridge Isotope Laboratories, MA and used without further
purification. A stock solution (20%) was prepared in
phosphate buffered saline and sterile filtered through a
0.2 μm filter. The appropriate quantity of the stock solu-
tion was added to glucose-free RPMI medium to a final
concentration of 10.7 mM (excluding the 0.54 mM unla-
beled glucose from the FCS).
Table 2: Quantification of 13C enrichment in cellular metabolites 
by 1H NMR analysis: Glycolysis. 
Condition %13CAla %13C Lac 13CAla/Thr 13CAla/Thr
Rh30 (FCS) 74 ± 2 86 ± 2 2.9 ± 0.3 6.7 ± 0.3
Rh30 (BSA) <5 73 ± 2 <0.1 3.2 ± 0.3
Myocytes 44 ± 2 82 ± 2 0.7 ± 0.1 6.8 ± 0.3
%13C was calculated as described in the methods.Molecular Cancer 2008, 7:79 http://www.molecular-cancer.com/content/7/1/79
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TOCSY Spectra of Rh30 cell extract Figure 9
TOCSY Spectra of Rh30 cell extract. Expansion of the spectrum shown in Figure 8. A. Glu/Ala/Lac region expansion from 
A. The boxes show the 13C satellite peaks for Ala, Lac and Glu and the absence of labeling in Pro and Thr. Ala and lactate show 
only fully unlabeled and fully labeled cross peak patterns, whereas the Glu cross peak patterns exhibit both singly and doubly 
labeled isotopomer species (cf. [35]. B. The partial TOCSY spectral region displays the cross-peak patterns of singly and doubly 
labeled species for the 5- and 6-ring protons of 5'UXP.
A 
BMolecular Cancer 2008, 7:79 http://www.molecular-cancer.com/content/7/1/79
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13C labeling patterns in products of glycolysis, PPP and mitochondrial Krebs cycle with [U-13C]-Glc as tracer. Figure 10
13C labeling patterns in products of glycolysis, PPP and mitochondrial Krebs cycle with [U-13C]-Glc as tracer. 
The Krebs' cycle reactions are depicted without (panel A) or with (panel B) anaplerotic pyruvate carboxylation (PC) and the 
labeling patterns illustrated represent one turn of cycle activity. Two distinct 13C labeling patterns in Glu result from the cycle 
reactions with (panel B) or without PC (panel A), i.e. 13C labeling at C2,3 or C4,5, respectively. Isotopic scrambling occurs at 
the symmetric succinate, leading to the redistribution of 13C labels into C1 and C2 or C3 and C4 (panel A). Also depicted in 
panel B is the malate/Asp shuttle across the mitochondrial membrane, where the export of [13C-1,2,3]-Asp into the cytosol 
leads to the synthesis of [13C-1,2,3]-malate. Red C and green C represent 13C labeled carbons; solid and dashed arrows denote 
single and multi-step reactions, respectively; open arrows in panel A delineate unlabeled starting oxaloacetate (OAA) from 
13C-labeled OAA after one turn; open arrow in panel B denotes the start of a second cycle; double headed arrows indicate 
reversible or exchange reactions; SCS denotes succinyl CoA synthetase.Molecular Cancer 2008, 7:79 http://www.molecular-cancer.com/content/7/1/79
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Methods
Initial experiments were carried out with unlabeled glu-
cose, followed by full metabolite profile experiments
using [U-13C]-glucose. In one experiment, both the Rh30
and myocytes were cultured for 24 h in labeled glucose. In
a second experiment to account for the differences in cell
doubling rates, the Rh30 cells were cultured for 24 h, and
the myocytes for 48 h in the labeled glucose. In this work,
13C atoms in various metabolites deriving exclusively
from [U-13C]-glucose were monitored by NMR or mass
spectrometry, which represented de novo metabolic trans-
formations originating from glucose. Growth rates and
viability were measured by direct cell counting on a
hemocytometer using 0.4% Trypan Blue.
Metabolite extraction
After growth for 24 or 48 h the cells were harvested by
trypsinization, scraping followed by low spin centrifuga-
tion at 4°C. The pellet was washed twice with ice-cold PBS
to remove contaminating medium, pelleted again, flash
frozen in lN2 and lyophilized. The dry cell mass was
recorded for normalizing metabolite concentrations
before extractions twice with ice-cold 10% trichloroacetic
acid (TCA), followed by lyophilization as previously
described[37,53]. The dry mass of the cells was recorded
for normalizing metabolite concentrations. The medium
was similarly treated with TCA in the same way for meas-
uring secreted metabolites (predominantly lactate and
Ala), and to assay the glucose utilization during the exper-
iment. 13C-glucose was quantified at t = 0 and at harvest
(t) by1H NMR using the well-resolved 13C1 satellite sig-
nals of -α glucose centered at 5.22 ppm. This accounts for
36% of the total glucose. The 13C and 12C lactate and Ala
concentrations were determined by integration of the
methyl peak and its satellites and calibrated against the
concentration of lactate determined independently by
GC-MS. From this, the amount of glucose consumed,
ΔGlc, and the fraction converted to lactate plus Ala, F,
could be estimated, according to Eq. (1) and Eq. (2) [35]:
ΔGlc = n(13C-Glc)0-n(13C-Glc)t]( 1 )
F = [n(13C-lac) + n(13CAla)]/2ΔGlc (2)
n is the number of moles of the compound in parenthe-
ses.
The factor of 2 accounted for the fact that one molecule of
glucose gives rise to two molecules of lactate or Ala.
1-F then represents the glucose carbon that enters other
metabolites and macromolecules in the cell mass or oth-
erwise not accounted for. The fractions were not been cor-
rected for the small (5%) contribution from unlabeled
glucose present in the medium.
NMR
NMR spectra were recorded at either 14.1 T or 18.8 T on
Varian Inova NMR spectrometers at 20°C using a 90°
excitation pulse. One-dimensional NMR spectra were
recorded with an acquisition time of 2 sec and a relaxation
delay of 3 sec. Under these conditions, the protons were
essentially full relaxed, as determined by independent
measurements of the spin-lattice relaxation time, T1. For
identifying metabolites in the extracts and determining
the positional enrichment with 13C we used a suite of 2D
experiments including TOCSY (or DQ COSY), HSQC,
HCCH-TOCSY and HSQC-TOCSY as previously described
[35-37,53]. The latter two experiments make use of the
isotope editing function. HCCH-TOCSY specifically
selects for those molecules in which at least two adjacent
carbon atoms are 13C whereas HSQC or HSQC-TOCSY
detects protons directly attached to 13C. The TOCSY exper-
iments were recorded with a spectral width of 6000 Hz in
F2, 0.341 s acquisition time in t2 and 0.05 s in t1, 1.9 s
interpulse delay, 50 ms mixing time, and an 8 kHz B1 field
strength. The HSQC-TOCSY experiments were recorded
with an acquisition time of 0.12 s in t2 and 12 ms in t1
using a 50 ms proton spin lock at a strength of 8 kHz. For
the HCCH-TOCSY experiments, the acquisition times
were 0.12 s in t2, 0.05 s in t1 using an 8 kHz 13C spin lock
field centered in the aliphatic region of the spectrum for a
duration of 12 ms.
Metabolites were assigned based on their 1H chemical
shift, TOCSY connectivity patterns and correlation with
13C, using our in-house database as described previously
[36,54]. All metabolites except choline, sugars and the
nucleotides were quantified from GC-MS data [55]
whereas choline was quantified from the peak at 3.22
ppm in the 1-D NMR spectra, as described previously
[56].
NMR analysis of 13C enrichment
13C enrichment in lactate and Ala was determined from
1D  1H NMR experiments, as the methyl resonances of
these metabolites were well resolved. The peaks were inte-
Table 3: Quantification of 13C enrichment in cellular metabolites 
by 1H NMR analysis: Pentose phosphate and pyrimidine 
biosynthesis
Ribose ring Base ring
Condition %13C Pur %13C Pyr [%13C Uri
Rh30 (FCS) 95 ± 2 80 ± 2 50 ± 3(26 ± 2)a
Rh30 (BSA) 82 ± 2 88 ± 2 45 ± 2(21 ± 2)a
Myocytes >90 <5 <5
a All 4 possible isotopomers at the C5, C6 positions were observed. 
first entry: percentage of all forms of 13C5 and 13C6 of U. The value in 
parenthesis the percentage of doubly labeled C5 and C6.Molecular Cancer 2008, 7:79 http://www.molecular-cancer.com/content/7/1/79
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grated, and the areas of the protons attached to 12C (cen-
tral peak) and to 13C (satellite peaks) were recorded. The
13C content was then calculated as [35]:
%13C = 100*area(13C satellites)/
[area(12C)+area(13Csatellites)] (3)
For other metabolites, which were not resolved in 1D
NMR experiments, we volume-integrated cross-peaks in
TOCSY spectra after correcting the base-planes. The vari-
ous isotopomer enrichments were calculated as for the 1D
spectra, i.e. the peak volume of the particular 13C iso-
topomer divided by the total volume of the cross peak
including the satellites. In the TOCSY experiments, the
protons were partially saturated owing to the shorter recy-
cle time (2 s) of these experiments. Thus, the actual peak
volumes were corrected according to the differential T1
values of protons attached to 13C or 13C; as:
M(true) = M(obs)/[1-exp-t/T1]( 4 )
Where M(true) is the corrected area, M(obs) is the
observed area, and t is the recycle time. As the relaxation
during the spin lock has the opposite effect on peak inten-
sities, this correction was small [35]. Effective T1 values
were determined on standards recorded under the same
solvent conditions.
GC-MS
Following NMR analysis, an aliquot (50–100 μl) of the
NMR sample was re-equilibrated with H2O and lyophi-
lized to remove any deuteration, then silylated with 25–
50 μl 1:1 (v/v) acetonitrile:MTBSTFA (N-methyl-N-[tert-
butyldimethylsilyl]trifluoroacetamide, (Regis Chemical,
Morton Grove, IL) by 3 h of sonication followed by stand-
ing overnight [57,58]. The solution was directly analyzed
on a PolarisQ GC-ion trap MSn (ThermoFinnigan, Austin,
TX) using a 0.5 μl injection volume. The column was 0.15
mm i.d. × 50 m fused silica open-tubular, coated with 0.2
μm BPX-5 (5% phenyl-methylsiloxane). The following
conditions were employed for GC-MS. Injector at 280°C,
column at 60°C for 2 min, followed by a 20°C/min ramp
to 150°C, then 6°C/min to 300°C, splitless vent held for
1.5 min, He carrier gas velocity 30 cm/s at 60°C, transfer
line = 280°C, electron energy = 70 eV, source heated to
190°C, automatic gain control target value = 50, maxi-
mum inject time = 25 ms, He damping gas = 0.3 ml/min,
full scan acquisition from 140 to 650 m/z at a rate of five
spectra/s which were averaged into one, and mass calibra-
tion preformed byperfluorotributylamine.
Metabolites were identified and quantified automatically
using Xcalibur software (ThermoFinnigan), based on their
GC retention times and mass fragmentation patterns
matched against an in-house database and external stand-
ards. Identities were also verified by manual inspection.
GC-MS quantification of total abundance of metabolites
was accomplished by comparing the m/z 147 ion
response for each metabolite in the samples with that for
the corresponding standard of known concentration. The
m/z 147 ion was chosen for quantification of labeled
Table 4: Quantification of 13C enrichment in cellular glutamate by 1H NMR analysis.
% 12C or 13C
Condition 12α12γ 12α13γ 13α12γ 13α13γ 12α12β 12α13β 13α12β 13α13β
Rh30 (FCS) 46 ± 3 11 ± 2 14 ± 2 29 ± 3 63 ± 3 2.5 ± .5 6.7 ± 1 28 ± 2
Rh30 (BSA) 54 ± 3 16 ± 2 <2 30 ± 3 78 ± 4 <2 9 ± 1 13 ± 1
Myocytes 71 ± 3 9 ± 1 12 ± 2 7 ± 1 >90 <10 <2 <2
HCCH TOCSY spectrum of myocyte cell extract Figure 11
HCCH TOCSY spectrum of myocyte cell extract. 48 
h myoctye cells and 24 h Rh30 cells grown in the presence of 
[U-13C]-glucose were extracted as described in the methods. 
1D NMR spectra were recorded at 18.8 T as described in 
the methods and elsewhere[35]. The HCCH TOCSY spec-
trum of the myocyte extract was recorded with a mixing 
time of 12 ms showing cross peak patterns of consecutively 
labeled carbons of glycogen resonances, G6P and fully labeled 
ribose moieties of nucleotides (e.g. 5'AXP), lactate, Ala, and 
Glu.Molecular Cancer 2008, 7:79 http://www.molecular-cancer.com/content/7/1/79
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amino acids because this ion fragment did not contain 13C
as it originated entirely from the silyl moiety. Conversely,
for 13C isotopomers, the pseudo-molecular ion clusters of
authentic standards were used to obtain the empirical ion
ratios as the basis of the calculation for label abundance,
as described in detail previously [37].
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HSQC TOCSY spectrum of myocyte cell extract Figure 12
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